Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2001-12-19
This is a multicenter study to evaluate potential decrease in hospitalization events and time
between events and increasing longevity in patients with symptomatic congestive heart failure
and intolerant of first-line medication for heart failure. This study will evaluate if higher
doses of the investigational drug given daily will be superior to the lower dose of the same
investigational drug given daily.
ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)
Completed
Merck Sharp & Dohme Corp.
Phase 4
2000-03-14
To demonstrate that losartan (+ conventional therapy) compared to placebo (+ conventional
therapy) will reduce the number of RT patients who experience histological lesions of chronic
allograft nephropathy
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
